摘要
目的:评价依达拉奉联合疏血通注射液治疗急性脑梗死大鼠的疗效和安全性。方法:将SD大鼠随机分为:假手术组、模型组、依达拉奉组、疏血通组、依达拉奉联合疏血通组,采用线栓法复制大鼠左侧大脑中动脉脑缺血(middle cerebral artery occlusion,MCAO)模型,除假手术组外,每组按不同时间点(1、3、5、7d)分为4个亚组,术后各组腹腔注射相应药物,1次/d,连续给药1、3、5、7d,模型组、假手术组分别予以等体积0.9%氯化钠溶液,观察比较各组大鼠神经功能缺损评分、脑组织梗死体积、脑组织含水量、脑组织形态学改变及白细胞计数(WBC)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(Cr)、尿素氮(BUN)、磷酸肌酸激酶(CK)、乳酸脱氢酶(LDH)、活化部分凝血活酶时间(APTT)等变化。结果:与假手术组比较,其余各组神经功能缺损评分、脑组织含水量、脑梗死体积均显著增高(P<0.05,P<0.01);与模型组比较,各用药组的神经功能缺损评分、脑组织含水量、脑梗死体积和安全性评价指标(WBC、AST、APTT)均有不同程度降低(P<0.05,P<0.01);与依达拉奉组、疏血通组比较,联合用药组的神经功能缺损评分、脑组织含水量、脑梗死体积减少更明显(P<0.05,P<0.01),安全性指标差异无统计学意义。结论:依达拉奉联合疏血通在改善大鼠神经功能缺损症状、减少脑梗死体积、减轻脑水肿3个方面均优于依达拉奉组、疏血通组,且不良反应发生率低,安全性较好。
Objective: To evaluate the efficacy and safety of edaravone combined with Shuxuetong Injection in the treatment of acute cerebral infarction rats. Methods: SD rats were randomly divided into sham operation group, model group. edaravone group, shuxuetong group and edaravone combined with shuxuetong group. The left middle cerebral artery cerebral ischemia(MCAO) model was established by using suture method. Except for sham operation group, each group was divided into 4 subgroups according to different time points(1, 3, 5, 7d). The rats in each group were injected intraperitoneally with the corresponding drugs, 1 times/d, continuous administration for 1, 3, 5, 7d. The rats in the model group and the sham operation group were treated with equal volume of 0.9% sodium chloride solution, the neurological deficit score, brain infarct volume, brain tissue water content, brain histomorphology and white blood cell count(WBC), alanine aminotransferase(ALT), aspartate aminotransferase(AST), creatinine(Cr), urea nitrogen(BUN), creatine phosphokinase(CK), lactate dehydrogenase(LDH), activated partial thromboplastin time(APTT) were observed and compared. Results: Compared with the sham group, the scores of neurological deficits, brain tissue water content and cerebral infarct volume in the remaining groups were significantly increased(P<0.05, P<0.01). Compared with the model group, the scores of neurological deficits, brain tissue water content, cerebral infarction volume and safety evaluation index(WBC, AST, APTT) of each medication group were decreased in different degress(P<0.05, P<0.01). Compared with edaravone group and shuxuetong group, the scores of neurological deficits, brain tissue water content and cerebral infarct volume of the combination group were more decreased(P<0.05, P<0.01), and there was no significant difference in safety index. Conclusion: The combination of edaravone group and shuxuetong group was better than that of edaravone group and shuxuetong group in improving the symptoms of neurological deficits, re
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2017年第9期4243-4248,共6页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
湖南省科技厅重点项目(No.2014SK2007)~~
